Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$3.83K$3.83K−88.1% vs Q3 2019 Net Income-$150.55K-$150.55KN/M vs Q3 2019 EPS Diluted-$0.59-$0.59N/M vs Q3 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Cash Flowderived-$60,910N/M Margins · derivedGross margin53.1%−22.0 pt vs Q3 2019
Operating margin-2284.2%−1901.9 pt vs Q3 2019
Net margin-3926.6%−3494.9 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 9, 2020 · 40 d after period end